226 related articles for article (PubMed ID: 18687705)
1. Enhanced pulsatile pressure accelerates vascular smooth muscle migration: implications for atherogenesis of hypertension.
Tada T; Nawata J; Wang H; Onoue N; Zhulanqiqige D; Ito K; Sugimura K; Fukumoto Y; Shimokawa H
Cardiovasc Res; 2008 Dec; 80(3):346-53. PubMed ID: 18687705
[TBL] [Abstract][Full Text] [Related]
2. Pulse pressure to vascular cells: novel methods for solving pathogenesis in cell migration.
Ishida Y
Cardiovasc Res; 2008 Dec; 80(3):326-7. PubMed ID: 18829700
[No Abstract] [Full Text] [Related]
3. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan.
Iwai M; Li HS; Chen R; Shiuchi T; Wu L; Min LJ; Li JM; Tsuda M; Suzuki J; Tomono Y; Tomochika H; Mogi M; Horiuchi M
J Pharmacol Exp Ther; 2006 Dec; 319(3):1081-7. PubMed ID: 16990512
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension.
Sendra J; Llorente-Cortés V; Costales P; Huesca-Gómez C; Badimon L
Cardiovasc Res; 2008 Jun; 78(3):581-9. PubMed ID: 18281370
[TBL] [Abstract][Full Text] [Related]
5. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
[TBL] [Abstract][Full Text] [Related]
6. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of olmesartan and azelnidipine on atrial structural remodeling in spontaneously hypertensive rats.
Okamura K; Ito M; Tanaka K; Chinushi M; Adachi T; Mitsuma W; Hirono S; Nakazawa M; Kodama M; Aizawa Y
Pharmacology; 2009; 83(6):360-6. PubMed ID: 19440002
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner.
Ishizawa K; Izawa-Ishizawa Y; Dorjsuren N; Miki E; Kihira Y; Ikeda Y; Hamano S; Kawazoe K; Minakuchi K; Tomita S; Tsuchiya K; Tamaki T
Nephrol Dial Transplant; 2010 Feb; 25(2):364-72. PubMed ID: 19812233
[TBL] [Abstract][Full Text] [Related]
9. Implication of multiple signaling pathways in the regulation of angiotensin II induced enhanced expression of Giα proteins in vascular smooth muscle cells.
Li Y; Anand-Srivastava MB
Can J Physiol Pharmacol; 2012 Aug; 90(8):1105-16. PubMed ID: 22784310
[TBL] [Abstract][Full Text] [Related]
10. Comparative effects of azelnidipine and other Ca2+-channel blockers on the induction of inducible nitric oxide synthase in vascular smooth muscle cells.
Ma J; Kishida S; Wang GQ; Meguro K; Imuta H; Oonuma H; Iida H; Jo T; Takano H; Morita T; Nagai R; Nakajima T
J Cardiovasc Pharmacol; 2006 Feb; 47(2):314-21. PubMed ID: 16495772
[TBL] [Abstract][Full Text] [Related]
11. Effect of azelnidipine on angiotensin II-mediated growth-promoting signaling in vascular smooth muscle cells.
Li JM; Iwai M; Cui TX; Min LJ; Tsuda M; Iwanami J; Suzuki J; Mogi M; Horiuchi M
Mol Pharmacol; 2005 May; 67(5):1666-73. PubMed ID: 15695623
[TBL] [Abstract][Full Text] [Related]
12. Prevention of vascular injury by combination of an AT1 receptor blocker, olmesartan, with various calcium antagonists.
Inaba S; Iwai M; Tomono Y; Senba I; Furuno M; Kanno H; Okayama H; Mogi M; Higaki J; Horiuchi M
Am J Hypertens; 2009 Feb; 22(2):145-50. PubMed ID: 19057515
[TBL] [Abstract][Full Text] [Related]
13. Effect of combination of calcium antagonist, azelnidipine, and AT1 receptor blocker, olmesartan, on atherosclerosis in apolipoprotein E-deficient mice.
Suzuki J; Iwai M; Li Z; Li JM; Min LJ; Ide A; Yoshii T; Oshita A; Mogi M; Horiuchi M
J Hypertens; 2005 Jul; 23(7):1383-9. PubMed ID: 15942461
[TBL] [Abstract][Full Text] [Related]
14. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
Guo Q; Minami N; Mori N; Nagasaka M; Ito O; Kurosawa H; Kanazawa M; Kohzuki M
Hypertens Res; 2008 Mar; 31(3):525-33. PubMed ID: 18497473
[TBL] [Abstract][Full Text] [Related]
15. Intracellular angiotensin II activates rat myometrium.
Deliu E; Tica AA; Motoc D; Brailoiu GC; Brailoiu E
Am J Physiol Cell Physiol; 2011 Sep; 301(3):C559-65. PubMed ID: 21613610
[TBL] [Abstract][Full Text] [Related]
16. Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase.
Redmond EM; Cahill PA; Hirsch M; Wang YN; Sitzmann JV; Okada SS
Thromb Haemost; 1999 Feb; 81(2):293-300. PubMed ID: 10064009
[TBL] [Abstract][Full Text] [Related]
17. Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways.
Kyotani Y; Zhao J; Tomita S; Nakayama H; Isosaki M; Uno M; Yoshizumi M
J Pharmacol Sci; 2010; 113(2):161-8. PubMed ID: 20508392
[TBL] [Abstract][Full Text] [Related]
18. Hemodynamic influences of azelnidipine, a novel calcium channel blocker, on cerebral circulation in hypertensive patients with ischemic white matter lesions.
Kimura Y; Kitagawa K; Oku N; Kajimoto K; Kato H; Tanaka M; Sakaguchi M; Hougaku H; Sakoda S; Hatazawa J
Hypertens Res; 2008 Dec; 31(12):2147-54. PubMed ID: 19139604
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous treatment with azelnidipine and olmesartan inhibits apoptosis of Hl-1 cardiac myocytes expressing E334k cMyBPC.
Bahrudin U; Ikeda N; Utami SB; Maharani N; Morikawa K; Li P; Sobirin MA; Hasegawa A; Sakata S; Endo R; Rifqi S; Shirayoshi Y; Yamamoto K; Ninomiya H; Hisatome I
Drug Res (Stuttg); 2013 Oct; 63(10):515-20. PubMed ID: 23740383
[TBL] [Abstract][Full Text] [Related]
20. Ethanol inhibits pulse pressure-induced vascular smooth muscle cell migration by differentially modulating plasminogen activator inhibitor type 1, matrix metalloproteinase-2 and -9.
Cullen JP; Sayeed S; Kim Y; Theodorakis NG; Sitzmann JV; Cahill PA; Redmond EM
Thromb Haemost; 2005 Sep; 94(3):639-45. PubMed ID: 16268483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
